213 related articles for article (PubMed ID: 31325668)
1. Safety and efficacy of edaravone compared to historical controls in patients with amyotrophic lateral sclerosis from North-Eastern Italy.
Fortuna A; Gizzi M; Bello L; Martinelli I; Bertolin C; Pegoraro E; Corbetta M; Sorarù G;
J Neurol Sci; 2019 Sep; 404():47-51. PubMed ID: 31325668
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of edaravone in treatment of amyotrophic lateral sclerosis-a systematic review and meta-analysis.
Luo L; Song Z; Li X; Huiwang ; Zeng Y; Qinwang ; Meiqi ; He J
Neurol Sci; 2019 Feb; 40(2):235-241. PubMed ID: 30483992
[TBL] [Abstract][Full Text] [Related]
3. Safety and Effectiveness of Long-term Intravenous Administration of Edaravone for Treatment of Patients With Amyotrophic Lateral Sclerosis.
Witzel S; Maier A; Steinbach R; Grosskreutz J; Koch JC; Sarikidi A; Petri S; Günther R; Wolf J; Hermann A; Prudlo J; Cordts I; Lingor P; Löscher WN; Kohl Z; Hagenacker T; Ruckes C; Koch B; Spittel S; Günther K; Michels S; Dorst J; Meyer T; Ludolph AC;
JAMA Neurol; 2022 Feb; 79(2):121-130. PubMed ID: 35006266
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of clinical outcome and safety profile of edaravone in treatment of amyotrophic lateral sclerosis: a 72-week single-center experience.
Ismail II; Massoud F; Kamel WA; Al-Hashel JY
Acta Neurol Belg; 2021 Dec; 121(6):1591-1597. PubMed ID: 32651875
[TBL] [Abstract][Full Text] [Related]
5. Long-term edaravone efficacy in amyotrophic lateral sclerosis: Post-hoc analyses of Study 19 (MCI186-19).
Shefner J; Heiman-Patterson T; Pioro EP; Wiedau-Pazos M; Liu S; Zhang J; Agnese W; Apple S
Muscle Nerve; 2020 Feb; 61(2):218-221. PubMed ID: 31621933
[TBL] [Abstract][Full Text] [Related]
6. Early post-marketing experience with edaravone in an unselected group of patients with ALS.
Abraham A; Nefussy B; Fainmesser Y; Ebrahimi Y; Karni A; Drory VE
Amyotroph Lateral Scler Frontotemporal Degener; 2019 May; 20(3-4):260-263. PubMed ID: 30784320
[No Abstract] [Full Text] [Related]
7. Assessment of Use and Safety of Edaravone for Amyotrophic Lateral Sclerosis in the Veterans Affairs Health Care System.
Vu M; Tortorice K; Zacher J; Dong D; Hur K; Zhang R; Good CB; Glassman PA; Cunningham FE
JAMA Netw Open; 2020 Oct; 3(10):e2014645. PubMed ID: 33017028
[TBL] [Abstract][Full Text] [Related]
8. Effect of edaravone therapy in Korean amyotrophic lateral sclerosis (ALS) patients.
Park JM; Kim SY; Park D; Park JS
Neurol Sci; 2020 Jan; 41(1):119-123. PubMed ID: 31471712
[TBL] [Abstract][Full Text] [Related]
9. Exploratory double-blind, parallel-group, placebo-controlled study of edaravone (MCI-186) in amyotrophic lateral sclerosis (Japan ALS severity classification: Grade 3, requiring assistance for eating, excretion or ambulation).
WRITING GROUP ON BEHALF OF THE EDARAVONE (MCI-186) ALS 18 STUDY GROUP
Amyotroph Lateral Scler Frontotemporal Degener; 2017 Oct; 18(sup1):40-48. PubMed ID: 28872915
[TBL] [Abstract][Full Text] [Related]
10. Edaravone for the treatment of amyotrophic lateral sclerosis.
Yoshino H
Expert Rev Neurother; 2019 Mar; 19(3):185-193. PubMed ID: 30810406
[TBL] [Abstract][Full Text] [Related]
11. Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients.
Abe K; Itoyama Y; Sobue G; Tsuji S; Aoki M; Doyu M; Hamada C; Kondo K; Yoneoka T; Akimoto M; Yoshino H;
Amyotroph Lateral Scler Frontotemporal Degener; 2014 Dec; 15(7-8):610-7. PubMed ID: 25286015
[TBL] [Abstract][Full Text] [Related]
12. Is edaravone harmful? (A placebo is not a control).
Turnbull J
Amyotroph Lateral Scler Frontotemporal Degener; 2018 Nov; 19(7-8):477-482. PubMed ID: 30373406
[TBL] [Abstract][Full Text] [Related]
13. Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs.
Jaiswal MK
Med Res Rev; 2019 Mar; 39(2):733-748. PubMed ID: 30101496
[TBL] [Abstract][Full Text] [Related]
14.
Palumbo JM; Hubble J; Apple S; Takei K; Tsuda K; Liu S; Zhang J; Agnese W
Amyotroph Lateral Scler Frontotemporal Degener; 2019 Aug; 20(5-6):421-431. PubMed ID: 30982356
[No Abstract] [Full Text] [Related]
15. Exploratory double-blind, parallel-group, placebo-controlled extension study of edaravone (MCI-186) in amyotrophic lateral sclerosis.
WRITING GROUP ON BEHALF OF THE EDARAVONE (MCI-186) ALS 17 STUDY GROUP
Amyotroph Lateral Scler Frontotemporal Degener; 2017 Oct; 18(sup1):20-31. PubMed ID: 28872918
[TBL] [Abstract][Full Text] [Related]
16. Safety and Efficacy of Edaravone in Patients with Amyotrophic Lateral Sclerosis: A Systematic Review and Meta-analysis.
Gao M; Zhu L; Chang J; Cao T; Song L; Wen C; Chen Y; Zhuo Y; Chen F
Clin Drug Investig; 2023 Jan; 43(1):1-11. PubMed ID: 36462105
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Edaravone in Amyotrophic Lateral Sclerosis Patients in Indian Population.
Tomar S; Gupta S; Singal A; Soni R
J Assoc Physicians India; 2022 Apr; 70(4):11-12. PubMed ID: 35443425
[TBL] [Abstract][Full Text] [Related]
18. Edaravone for patients with amyotrophic lateral sclerosis: a systematic review and meta-analysis.
Huang SL; Shen YL; Peng WY; Ye K; Zheng H
Acta Neurol Belg; 2024 Jun; 124(3):895-904. PubMed ID: 38347315
[TBL] [Abstract][Full Text] [Related]
19. Open-label 24-week extension study of edaravone (MCI-186) in amyotrophic lateral sclerosis.
WRITING GROUP ON BEHALF OF THE EDARAVONE (MCI-186) ALS 19 STUDY GROUP
Amyotroph Lateral Scler Frontotemporal Degener; 2017 Oct; 18(sup1):55-63. PubMed ID: 28872920
[TBL] [Abstract][Full Text] [Related]
20. Serum uric acid level predicts the progression of amyotrophic lateral sclerosis following treatment with edaravone.
Han HJ; Shin HY; Choi YC; Kim SM; Kim SW
Redox Rep; 2022 Dec; 27(1):79-84. PubMed ID: 35296219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
